Arbutus Biopharma (ABUS) Tops Q1 EPS by 5c

Arbutus Biopharma (NASDAQ: ABUS) reported Q1 EPS of ($0.11), $0.05 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $12.6 million versus the consensus estimate of $4.37 million.

For earnings history and earnings-related data on Arbutus Biopharma (ABUS) click here.

You May Also Be Interested In

• NVIDIA stock gains as SemiAnalysis sees H2 data center revenue 20% above consensus
• Alcoa agrees to buy South32 assets for $4.1 billion
• Oppenheimer turns cautious on major U.S. banks, favors alternative asset managers